Benjamin P. Saylor
Benjamin P. Saylor is associate editor of Urology Times, an Advanstar Communications publication.
Urology Product Preview: Testosterone agent meets efficacy endpoint in phase III studies
Drugs and devices in the pipeline form Clarus Therapeutics, Nymox Pharmaceutical, Bioniche Life Sciences, Repros Therapeutics, BioLight Life Sciences Investments/Micromedic Technologies, Cubist Pharmaceuticals, Takeda Pharmaceutical, H. Lundbeck A/S, Transplant Genomics, Orion, Bayer, and Roche.
ERSPC: PSA screening cuts PCa deaths by one-fifth
Recently published data from the European Randomised Study of Screening for Prostate Cancer (ERSPC) indicate that screening for prostate cancer could reduce deaths from the disease by about one-fifth.
FDA rejects petition for black box warning on T meds
The FDA has rejected Public Citizen’s petition to have a black box warning placed on the labels of testosterone-containing drugs available in the United States.
Rising temperatures linked to increased stone risk
Increasing daily temperature appears to be associated with an increased risk of kidney stones, results of a recently published multicenter study suggest.
Robot diffusion linked to increased adverse event risk
The widespread diffusion of minimally invasive robotic surgery for prostate cancer has been associated with an increase in the risk of adverse events, according to a recent study.
Best of AUA 2014: Minimally Invasive Surgery
Manish A. Vira, MD, presents the take home messages on minimally invasive surgery from the AUA annual meeting in Orlando, FL.
Best of AUA 2014: BPH/LUTS
Richard K. Lee, MD, MBA, presents the take home messages on BPH/LUTS from the AUA annual meeting in Orlando, FL.
Best of AUA 2014: Female Urology/Incontinence/Urodynamics
Adonis K. Hijaz, MD, presents the take home messages on female urology/incontinence/urodynamics from the AUA annual meeting in Orlando, FL, including studies on mesh outcomes and the overactive bladder treatment mirabegron (Myrbetriq).
Best of AUA 2014: Sexual Function/Dysfunction
Best of AUA 2014: Sexual Function/Dysfunction
Landon Trost, MD, presents the take home messages on sexual function/dysfunction from the AUA annual meeting in Orlando, FL, including studies of clostridium collagenase histolyticum (CCH [XIAFLEX]).
New study: No increased risk of MI with testosterone
A recent large study has found no increased risk of heart attack in men undergoing testosterone replacement therapy.

Poll

View Results